PepGen Inc is a Boston-based biotechnology company focused on developing a new generation of disease-modifying therapies for serious genetic neuromuscular and neurological disorders. Powered by their proprietary Enhanced Delivery Oligonucleotide (EDO) platform, they are committed to creating transformative therapies that target the root cause of these disorders.
With a pioneering approach to genetic therapies, PepGen is advancing a robust pipeline of therapeutics to treat conditions such as Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1). Their dedication to the community drives their mission to improve the lives of individuals living with neuromuscular and neurological disorders.
Generated from the website